Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554695 · ClinicalTrials.gov registry record · Early Phase 1
Osteoclast Inhibition and Bone Formation
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 81
- Enrollment target
NCT02554695: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT02554695 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02554695, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?
Interventions
- DRUG placebo
- DRUG denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-10-20 |
| Est. Completion | 2016-10-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02554695
The ClinicalTrials.gov registry entry for NCT02554695 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02554695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02554695 about?
NCT02554695 is a clinical study titled "Osteoclast Inhibition and Bone Formation". This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?
What is the current status of trial NCT02554695?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 81 participants. The study started on 2015-10-20. Estimated completion is 2016-10-25.
What interventions are being tested in trial NCT02554695?
The interventions under investigation include: placebo (DRUG), denosumab (DRUG).
Who is sponsoring clinical trial NCT02554695?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.